Investigational New Drug (IND) Applications

Investigational New Drug (IND) Applications - Overview

For conducting clinical trials with investigational drugs or drugs not approved for the intended use, the sponsor must submit an Investigational New Drug Application (INDA) to the United States Food and Drug Administration (US FDA) and obtain the Agency’s acceptance. Post the Investigational New Drug (IND) Application’s approval, the drug is transported or distributed across the US for use in clinical programs. What if the sponsor fails to submit adequate information in the IND application to assure product quality, safety, and scientific evidence on the proposed efficacy profile? In that case, the US FDA may issue a clinical hold (full clinical hold or partial clinical hold), restricting sponsors to move forward unless the issues are addressed. 

Freyr assists sponsors with end-to-end Regulatory support in IND programs, from pre-IND meetings to Regulatory compliance and management of late-phase submissions when the IND goes effective.

Investigational New Drug (IND) Applications - Freyr Expertise

  • Gap analysis of IND drug development data against the current Regulatory requirements for conducting human clinical trials and identifying potential clinical hold issues (Critical & Major).
  • Regulatory support for pre-IND meetings and other Agency communications (Type A, Type B, Type C, and Biosimilar Biological Product Development (BPD) meetings).
  • Request for Orphan Drug Designation (ODD) or expedited review program designations.
  • Strategic support in identifying the optimal Regulatory approach for an intended clinical program(s) and IND submission.
  • Expert advice on Regulatory mitigation plans for identified data deficiencies and clinical hold issues during the IND approval process.
  • Extensive understanding of NDA/BLA submission requirements and data correlations, from the IND to future Marketing Authorization Applications (MAAs).
  • Publishing and eCTD submission of initial INDs and subsequent submissions (IND annual reports, amendments, etc.).
  • Regulatory response strategy, preparation, and timely response submission to the US FDA queries/information requests.
  • Consulting support for IND inactivation or IND re-activation.
  • US agent services.
  • Preparation, technical reviews, and submission of CMC, nonclinical & clinical packages for initial IND submission, IND amendments, safety reporting, and IND annual reports submission in the eCTD format for different types of medicinal products (new chemical entities, vaccines, biosimilars, and other biological products like tissue and gene therapy products, etc.).
  • Investigational New Drug Application submission templates in eCTD format.


  • Blogs

    ANVISA Becomes a Member of PIC/s Committee

    ANVISA Becomes a Member of PIC/s Committee

    Read More
  • White Papers

    Factors that May Cause FDA to Refuse to Receive (RTR) an ANDA

    Factors that May Cause FDA to Refuse to Receive (RTR) an ANDA

    Read More
  • Webinars

    Strategic Regulatory Partnerships How to Evaluate & Engage with a Regulatory Partner

    Strategic Regulatory Partnerships How to Evaluate & Engage with a Regulatory Partner?

    Read More

What Our Clients Say?

Privacy Policy
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Quick Inquiry